Actelion Will Take Novel Sleep Therapy Into Phase III This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.You may also be interested in...
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.
Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug
Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.
GSK/Actelion: Phase III Value Is in the Eye of the Beholder
GSK paid a very large upfront fee ($148mm) for access to Actelion's Phase III insomnia candidate almorexant, but still some were disappointed; the Big Pharma is only paying 40% of the costs of the Phase III program. The truth is that even late-stage primary care assets--especially those with novel mechanisms of action--are under intense regulatory scrutiny and licensors are having to take on more risk.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: